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Abstract
Background: CD44 has long been associated with glioma invasion while, more recently, CD155 has been implicated in
playing a similar role. Notably, these two receptors have been shown closely positioned on monocytes.
Methods and Findings: In this study, an up-regulation of CD44 and CD155 was demonstrated in established and early-
passage cultures of glioblastoma. Total internal reflected fluorescence (TIRF) microscopy revealed close proximity of CD44
and CD155. CD44 antibody blocking and gene silencing (via siRNA) resulted in greater inhibition of invasion than that for
CD155. Combined interference resulted in 86% inhibition of invasion, although in these investigations no obvious evidence
of synergy between CD44 and CD155 in curbing invasion was shown. Both siRNA-CD44 and siRNA-CD155 treated cells
lacked processes and were rounder, while live cell imaging showed reduced motility rate compared to wild type cells.
Adhesion assay demonstrated that wild type cells adhered most efficiently to laminin, whereas siRNA-treated cells
(p,0.0001 for both CD44 and CD155 expression) showed decreased adhesion on several ECMs investigated. BrdU assay
showed a higher proliferation of siRNA-CD44 and siRNA-CD155 cells, inversely correlated with reduced invasion. Confocal
microscopy revealed overlapping of CD155 and integrins (b1, avb1 and avb3) on glioblastoma cell processes whereas siRNA-
transfected cells showed consequent reduction in integrin expression with no specific staining patterns. Reduced
expression of Rho GTPases, Cdc42, Rac1/2/3, RhoA and RhoB, was seen in siRNA-CD44 and siRNA-CD155 cells. In contrast to
CD44-knockdown and ‘double’-knockdown cells, no obvious decrease in RhoC expression was observed in CD155-
knockdown cells.
Conclusions: This investigation has enhanced our understanding of cell invasion and confirmed CD44 to play a more
significant role in this biological process than CD155. Joint CD44/CD155 approaches may, however, merit further study in
therapeutic targeting of infiltrating glioma cells.
Citation: Maherally Z, Smith JR, An Q, Pilkington GJ (2012) Receptors for Hyaluronic Acid and Poliovirus: A Combinatorial Role in Glioma Invasion? PLoS ONE 7(2):
e30691. doi:10.1371/journal.pone.0030691
Editor: Joseph Najbauer, City of Hope National Medical Center and Beckman Research Institute, United States of America
Received September 30, 2011; Accepted December 23, 2011; Published February 17, 2012
Copyright:  2012 Maherally et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by grants to GJP from Brain Tumour UK (http://www.braintumouruk.org.uk), Brain Tumour Research (http://www.
braintumourresearch.org), Brainstrust (http://www.brainstrust.org.uk/index.php), and the Isle of Man Anticancer Association. These are UK-based brain tumour
charities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Geoff.pilkington@port.ac.uk
Introduction
Local invasion of the brain by neoplastic glial cells is arguably
the most significant biological feature of primary brain tumours
which hinders successful therapy [1]. Glioma cell invasion of
surrounding brain tissue frequently precludes complete surgical
resection. Moreover, during this invasive procedure, cells tran-
siently arrest from the cell cycle [2], therefore leaving them
refractory to radiotherapy and the response to chemotherapy is
accordingly poor [3]. The complex machinery of invasion involves
key players including cell adhesion molecules, the extracellular
matrix (ECM), gangliosides, growth factors and cytokines as well
as the cytoskeletal elements [2].
ECM is central to the invasive behaviour of glioma cells,
mediated through its associations with integrins [4]. In primary
brain tumour, ECM is aberrantly overexpressed, providing a
permissive substrate for invasion [3,5]. Cell adhesion molecules
(CAMs) such as integrins, cadherins and immunoglobulin proteins
are involved in cell motility in response to soluble ECM proteins.
Amongst them, integrins, consisting of a and b subunits [6], are
key molecules on the cell surface which facilitate ECM/CAMs
interaction and binding. Integrins play their mediating role in
adhesive events during malignant transformation, tumour growth
and progression, invasion and metastasis by providing a physical
transmembrane link between the ECM and underlying cytoskel-
etal elements, which results in transduction of bidirectional signals
across the cell membrane [4]. CAMs sit at the top of many
signalling cascades that regulate actin and microtubule dynamics
through Rho GTPases [7].
CD44, the CAM originally described as the lymphocyte homing
receptor, is a polymorphic family of membrane glycoproteins [8].
CD44 is involved in a diverse range of physiological and
pathological processes including lymphocyte homing and activa-
tion, cell-ECM interactions, migration, tumour growth and
metastasis [9]. It has two isoforms with molecular weights of 80–
90 kDa and 150 kDa. The former isoform aids the attachment to
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30691
hyaluronic acid (HA), a component of ECM with relatively high
concentration in the brain [10,11] and also known to play a pivotal
role in glioma invasion [12]. The role of HA in invasion has been
described previously whereby cancer cells stimulate host cells to
produce and secrete HA via a paracrine growth factor mechanism,
known as HA stimulating activity [13]. In ECM, the secreted HA
undergoes hydration and swells to extend the extracellular space,
providing a pathway for neoplastic cell invasion. Invading cells can
then adhere to HA by way of cell surface receptors including
CD44 [14]. Having invaded into the new host tissue, invading
tumour cells secrete hyaluronidase to breakdown HA molecules,
giving rise to a pro-angiogenic product that facilitates continued
survival of the neoplasm [5]. Previous data have shown that CD44
is overexpressed in neoplastic cells and aids glioma cell adhesion
and invasion, through its interaction with HA and other ECM
components [15–17].
CD155, a transmembrane glycoprotein originally discovered as
the receptor for Poliovirus (PV), binds to vitronectin via its
extracellular domain [18]. CD155, although widely distributed
throughout human tissues, has a low level of expression that is
tightly controlled. Increased expression of CD155 has been shown
in tumours and recently Goetz et al. further reported an
upregulation of CD155 on tumour cells in glioblastoma multi-
forme (GBM) patients. This study also underlines the possible
association of CD155 with cancer stem cells which they have
exploited in an attempt to use non-pathogenic poliovirus
recombinant in preliminary therapeutic protocols [19]. Addition-
ally, CD155 is thought to play a key role in tumour cell migration,
enhancing cell adhesion signals and regulating focal adhesions
[20]. It has been reported that CD155 is recruited to the leading
edges of migrating cells where it co-localises with other migration
mediators, namely actin and integrins [20]. Inhibition of CD155
by siRNA-knockdown (siRNA-KD) in cultured glioma cells alters
cell morphology to a larger, more uniform phenotype with
resultant significant reduction in cell migration/invasion [20,21].
It was further stated by Enloe and Jay that inhibition of CD155 by
RNAi caused a decrease in tumour invasion in part through
reduced activity of matrix metalloproteinase-2 (MMP-2), a known
factor in GBM invasion [22].
Interestingly, a physical association has been revealed between
CD44 and CD155 on the cell membrane of monocytes where anti-
CD44 monoclonal antibody (mAb) inhibits the binding of anti-
CD155 mAb [23]. Similarly, anti-CD44 mAb hinders the binding
of poliovirus to CD155 due to its steric position [24]. These studies
reflect a close physical apposition between CD44 and CD155. It
has been suggested that CD44 may act as a co-receptor for cellular
uptake of poliovirus, however the localisation of CD44 in human
tissues does not correlate with poliovirus susceptibility [24]. Such
interaction between CD44 and CD155 and its implications have
yet to be researched in brain tumours. In particular, the role of
CD155 in brain tumours is still unclear and its potential as a
therapeutic target for invasive brain tumours remains to be
explored. In the present study, the juxtaposition of CD44 and
CD155 was observed on glioma cells and their interactive role in
cell migration/invasion was investigated in conjunction with
integrins at the cell surface.
Results
Expression and close proximity of CD44 and CD155 on
glioma cells
Expression of CD44 and CD155 on the surface of normal
astrocytes and GBM cells were analysed by ICC and flow
cytometry. CD44 was widely distributed over the cells but more
condensed on the leading membrane and ruffles (Fig. 1a–c).
CD155 was well distributed throughout the cells with more
condensed expression at cell-cell junctions, established points of
adhesion and the prominent filopodia (Fig. 1a–c). Total internal
reflected fluorescence (TIRF) microscopy was used to clarify
the exact location of CD44 and CD155, showing that CD44
and CD155 are closely physically apposed on the cell
membrane (Fig. 1c). Compared with normal astrocytes (CC-
2565), significantly higher expression of CD44 and CD155 in
GBM cell lines was demonstrated by flow cytometry (p,0.0001
for both CD44 and CD155 expression in terms of positive cell
population and fluorescence fold with the exception of UPMC
which showed a similar fluorescence fold to CC-2565 (p.0.05;
Fig. 1d).
Evaluation of siRNA-KD of CD44 and CD155
The effect of siRNA-KD was assessed by Western blotting, ICC
and flow cytometry. SNB-19 was employed in the knockdown
experiments. An AccellTM non-targeting pool siRNA was used as a
negative control to demonstrate a non-specific baseline cellular
response that could be compared to the levels in SNB-19 cells
treated with target-specific siRNA (i.e., CD44 and CD155).
Glyceraldehyde-3-phosphate dehydrogenase (GAPD)-siRNA was
used as a positive control for gene silencing and validation of
experimental design. Western blotting (WB) showed markedly
decreased band intensity for GAPD and CD155, whereas CD44
band suggested residual protein present in treated cells, using wild
type (wt) as well as non-targeting siRNA treated cells as controls
(Fig. 2a). WB data for non-targeting siRNA treatment confirmed
that sequence-specific knockdown of CD44 and CD155 was
achieved. ICC staining revealed the decreased expression of
CD44/CD155 and altered morphology of siRNA-KD cells
(Fig. 2b). Non-targeting siRNA treated cells (Fig. 2b, left panel)
showed well-defined, long processes extending at both ends,
whereas the siRNA-KD cells assumed a round shape and had no
processes (Fig. 2b, right panel). The degree of siRNA-KD was
further quantified by flow cytometry. Significant decline of positive
cell population and fluorescence fold was observed in siRNA-KD
SNB-19 cells compared with control, e.g., non-targeting siRNA
treated cells (p,0.0001 for both CD44 and CD155; Fig. 2c).
Decrease in invasion and increase in proliferation of SNB-
19 cells following CD44/CD155 monoclonal antibody
(mAb) blocking and siRNA-KD
The role of CD44 and CD155 in glioma cell invasion was
investigated by two approaches: mAb-blocking and siRNA-KD.
Antibody-blocking of CD44 or/and CD155 significantly inhibited
invasion of the GBM cells studied, compared with their wild type
counterparts (control) (p,0.0001; represented by SNB-19 in
Fig. 3a/left panel). In accordance with mAb-blocking, CD44/
CD155-siRNA significantly reduced invasiveness of SNB-19 cells
compared with non-targeting siRNA treated cells (control)
(p,0.0001; Fig. 3a/right panel).
The BrdU cell proliferation assay was performed to determine
the inverse relationship between invasion and proliferation as
previously reported [25]. A significant difference was observed
comparing manipulated SNB-19 cells with control cells. Wild type
SNB-19 cells gave a proliferation index of 0.168, which increased
to 0.341 and 0.326 in cells treated with mAb-CD44 and mAb-
CD155, respectively. Further increase of proliferation rate was
detected following simultaneous CD44/CD155-blocking, which
gave a value of 0.363 (p,0.0001; Fig. 3b). Similarly, proliferation
indices increased from 0.175 in non-targeting siRNA treated cells
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to 0.314, 0.333 and 0.375 in siRNA-CD44, siRNA-CD155 and
‘double’-KD cells, respectively (p,0.0001; Fig. 3b).
Decrease in velocity of cell movement and total distance
covered in CD44/CD155 siRNA-KD SNB-19 cells
CD44/CD155-KD SNB-19 cells were monitored by live cell
imaging to evaluate motility over a period of 72 h. Control cells
(non-targeting siRNA treated) showed the highest velocity of
0.026 mm/s. A marked decrease in velocity was noticed when cells
were silenced for CD44 (0.0092 mm/s). siRNA-CD155 cells
moved at a velocity of 0.0064 mm/s and the minimum velocity
was achieved by ‘double’-knockdown cells (0.0058 mm/s). Our
data suggest that CD44/CD155-KD significantly reduces glioma
cell movement rate (p,0.0001) (Fig. 4a). The distance moved over
72 h was also significantly affected by CD44/CD155-KD
(p,0.0001) (Fig. 4b). Control cells travelled the maximum distance
of 4222 mm whereas siRNA-CD44 and ‘double’-KD cells moved
only 1036 mm and 733 mm, respectively. A minimum distance of
549 mm was demonstrated by siRNA-CD155 cells.
Decrease in adhesive potential of SNB-19 cells following
mAb-blocking and CD44/CD155 siRNA-KD
The interaction of cells with each of the adhesive substrates,
i.e., fibronectin, laminin, vitronectin, tenascin C and collagen I,
was quantified for SNB-19 cells. Bovine serum albumin (BSA)
was used as a control substrate. In the mAb-blocking experi-
ments, control (wild type) and treated cells showed no significant
difference for BSA (p=0.442), while substantial decrease in
adhesive potential was observed in the ‘single’- and ‘double’-
blocking cells for fibronectin, laminin, tenascin C and collagen I
compared with wild type cells (p,0.05; Fig. 5a), with the
exception of mAb-CD44 in tenascin C treatment (p.0.05;
Fig. 5a). Interestingly, unlike the trend shown by the above
substrates, vitronectin demonstrated an increased interaction with
mAb-CD155 treated cells (p.0.05; Fig. 5a), whereas the adhesive
potential was reduced in mAb-CD44 and ‘double’-blocking cells
compared with control cells (p,0.001 and p.0.05, respectively;
Fig. 5a).
Unlike mAb-blocking, CD44/CD155 ‘double’-KD resulted in
significantly enhanced adhesive potential compared with control
SNB-19 cells (non-targeting siRNA treated) for BSA (p,0.05;
Fig. 5b). Generally, in accordance with the results from the mAb-
blocking experiments, ‘single’- and ‘double’-KD cells demonstrat-
ed significantly reduced interaction with fibronectin, laminin,
tenascin C and collagen I compared with control cells (p,0.01;
Fig. 5b). In the case of vitronectin, siRNA-CD44 cells showed the
lowest adhesion rate (p,0.001; Fig. 5b), whereas siRNA-CD155
and ‘double’-KD cells showed insignificant change in adhesive
potential compared with control (p.0.05; Fig. 5b).
Figure 1. Expression and close proximity of CD44 and CD155 on GBM cells. a–c, Co-staining of CD44 (red) and CD155 (green) on SNB-19
and UPAB cells; scale bars: 25 mm (a) and 10 mm (b–c). TIRF microscopy (c) clearly demonstrated the juxtaposition of CD44 and CD155. CD155 is
mainly expressed on the processes and invadapodia (arrows). d, Significantly increased expression of CD44 (top panel) and CD155 (bottom panel)
in GBM cells confirmed by flow cytometry, as assessed by the percentage of antigen-expressing cells and increase in fluorescence fold. * indicates
statistical significance compared to CC-2565, a normal human astrocyte cell line.
doi:10.1371/journal.pone.0030691.g001
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CD44 and CD155 knockdown is accompanied by
changes in integrin expression
ICC double staining of CD44/CD155 and F-actin/integrins
(b1, avb1 and avb3) was carried out with wild type UPAB, UPMC
and non-targeting siRNA treated SNB-19 cells (representative
confocal microscopy images shown in Figs. 6a & b). Intense
filamentous, thread-like F-actin staining was noted within UPAB
cells (Fig. 6a, left panels). Dense granular staining of b1-integrin
was clearly seen at the perinuclear membranes and in the forming
filopodia/invadopodia of the cell with some sparsely staining
across the cytoplasm (Fig. 6a, right panels). Granular staining of
avb1-integrin was evenly distributed across UPMC and SNB-19
cells with more intense expression around the perinuclear region
(Fig. 6b, left panels). avb3-integrin was sprinkled all over the cell
surface with aggregates at the end of the cell (Fig. 6b, right panels).
CD44 was well distributed across the cells with prominent staining
in the filopodia regions (Figs. 6a & b, top panels). CD155 staining
was also evenly distributed with dense expression zones at the
leading edges of the cells (Figs. 6a & b, bottom panels). A very low
degree of CD155/b1-integrin co-localisation was noticed (Fig. 6a,
right bottom panel) yet CD155/avb1-integrin co-localisation was
observed frequently around the peripheral edges of the cell (Fig. 6b,
left bottom panel). A certain degree of random CD155/avb3-
integrin co-localisation was also seen on SNB-19 cell surfaces
(Fig. 6b, right bottom panel). No obvious CD44/integrin co-
localisation was observed by confocal microscopy.
A consequent decline in the expression level of integrins and F-
actin was seen in CD44/CD155-KD SNB-19 cells (data not
shown) and the consistent results were obtained through WB as
demonstrated by the reduced intensity of bands compared with
non-targeting siRNA treated cells (control) (Fig. 6c).
CD44/CD15-KD is accompanied by changes in RHO
GTPase signalling pathways
To further investigate the role of CD44 and CD155 in cell
invasion and the possible intracellular pathways they might
regulate, certain key members of Rho GTPases (Cdc42, Rac 1/
2/3, RhoA, RhoB and RhoC) were analysed in SNB-19 cells after
CD44/CD155-KD. Western blotting detected high levels of the
proteins of interest in control cells (non-targeting siRNA treated),
whereas Rho GTPases were downregulated by CD44/CD155-
KD (Fig. 7). Interestingly, CD44-KD had a greater impact on the
expression of Cdc42 and RhoC compared with CD155-KD.
Although Rac 1/2/3 and RhoA were downregulated similarly by
siRNA-CD44 and siRNA-CD155, RhoA was nearly eliminated in
‘double’-KD cells, whereas Rac 1/2/3 level was similar to that in
‘single’-KD cells (Fig. 7). These data clearly indicate that CD44
and CD155 are involved in the intracellular signalling pathways.
The level of CD44 and CD155 was also analysed by Western
blotting to show whether silencing of one gene would alter the
expression of the other gene. Our data suggest that CD44 and
CD155 are not likely to regulate each other’s expression (Fig. 7).
Discussion
This study has revealed CD44 to exert a greater influence on
glioma invasion than CD155. A possible synergistic role between
Figure 2. Reduced expression of CD44 and CD155 following siRNA-KD in SNB-19 cells. a, siRNA-KD of CD44 and CD155 was confirmed by
Western blotting using both wild type (wt) and non-targeting siRNA treated cells as controls. GAPD-siRNA was used as a positive control to validate
the knockdown effect. b, Expression of CD44 (top panels) and CD155 (bottom panels) in non-targeting siRNA treated cells (control/left panels/
L) and relevant siRNA-KD (right panels/R) cells; scale bars: 25 mm. In control cells (L), CD44 is uniformly distributed with intense staining at the
edges of the cells (arrows) whereas CD155 is well distributed with dense staining zones at the leading edges of the cells (arrows). CD44/CD155
staining was reduced in the siRNA-KD cells with clearly altered morphology (R). c, CD44/CD155-KD was confirmed by flow cytometry. Expression
levels of CD44 and CD155 were significantly reduced in siRNA-KD SNB-19 cells as indicated by percentage of positive cells and fluorescence fold. *
indicates statistical significance compared to non-targeting siRNA treated cells (control).
doi:10.1371/journal.pone.0030691.g002
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the two receptors in the biological process, as suggested by their
physical proximity [23] and previous studies demonstrating that
blocking of CD44 impairs the receptor function of CD155 [24],
was not confirmed.
In accordance with previous studies [15–17,20–23,26], our data
show that CD44 and CD155 are highly expressed in glioma cells
and are closely juxtaposed on the cell membrane. In the present
study, CD44 was seen to be widely distributed over GBM cells but
condensed on the leading edge of cells and processes, relating to its
function as a CAM and attachment to HA. CD155 was also
distributed throughout the cells with condensed expression at cell-
cell junctions, adhesion points and on filopodia. These results are
consistent with findings that CD155 is recruited to the leading
edges of migrating cells and small areas of focal adhesion which
are potentially involved in polarisation and directional motility
[21,27,28].
Our previous studies have linked local invasion of glioma cells to
elevated level of CD44 [29–31]. Similarly, CD155 expression and
its interaction with ECM have been reported to play a key role in
glioma cell adhesion, migration and invasion [20,21,32]. In the
present study, upregulation of CD44 and CD155 was detected
in three GBM cell lines (UPAB, UPMC and SNB-19) and a
correlation between CD44/CD155 expression and cell invasive-
ness was observed, i.e., UPMC with the lowest CD44/CD155
level was less invasive compared with UPAB and SNB-19 (data not
shown). However, the underlying mechanisms of those phenom-
ena and the possible relationship between CD44 and CD155 in
glioma cell invasion have remained unclear. In the present study,
antibody-mediated blocking and siRNA-KD of CD44/CD155 in
GMB cells were accompanied by decreased invasiveness, con-
firming the role of CD44/CD155 in cell invasion. CD44 showed a
greater impact on cell invasion than CD155 as judged by the
mAb-blocking and siRNA-KD studies. However, no additive or
synergistic role of CD44/CD155 in curbing invasion was
demonstrated. In accordance with previous reports, an inverse
relationship between invasion and proliferation was also revealed
in this study [26,33]. Our data clearly demonstrate that CD44 and
CD155 play important roles in glioma cell invasion.
To better understand the role of CD44/CD155 in glioma cell
invasion, live cell imaging microscopy was applied to assess cell
movement velocity and total distance covered by SNB-19 cells.
The migration rate of SNB-19 cells was substantially reduced after
CD44/CD155-KD with the lowest velocity observed in the
‘double’-KD cells. Interestingly, although total distance SNB-19
Figure 3. CD44/CD155-depletion inhibited invasion but enhanced proliferation of SNB-19 cells. Wild type (untreated) SNB-19 cells were
used as a control in the mAb-blocking experiments; non-targeting siRNA treated SNB-19 cells were used as a control in the siRNA-KD experiments. a,
Significantly reduced invasion following mAb-blocking (left panel) and siRNA-KD (right panel) was shown compared to controls. All images have
scale bars of 50 mm. b, Proliferation was markedly increased in mAb-blocking (left panel) and siRNA-KD (right panel) cells compared to controls. *
indicates statistical significance.
doi:10.1371/journal.pone.0030691.g003
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cells travelled in the period of 72 h was consequently reduced in
CD44- and CD155-KD cells, the least distance was achieved by
CD155-KD cells instead of ‘double’-KD ones, suggesting possible
contribution of hampered directionality in CD155-KD cells. To
our knowledge, this is the first time that CD44 and CD155 are
shown to be able to promote an invasion-associated motility rate.
Additionally, morphological changes were observed in siRNA-
CD44 cells, consistent with the published report that CD44-
depleted cells are strikingly devoid of invadopodia [34]. This result
therefore confirms that overexpression of CD44 correlates with
glioma invasion [29]. CD155-silenced cells showed the same
trend to become round, devoid of any invadopodia as previously
shownby Sloan et al., whereby CD155 depletion led to cell
rounding up and absence of ruffles at the leading edges [20,21].
Morphological changes following CD44- and CD155-KD were
further supported by Western blotting data indicating significantly
decreasedexpression of F-actin, integrins av, b1, b3 and Rho
GTPases. Whilst Rho is involved in the bundling of actin filaments
into stress fibres and formation of focal adhesion complexes, Rac
plays a role in the polymerisation of actin to form lamellipodia and
membrane ruffles and Cdc42 is involved in the polymerisation of
actin to form filopodia [35]. Thus, reduction in their expression
renders the disorganisation of actin cytoskeleton and the inability
of actin to form protrusions involved in cell invasion, leading to a
more uniform and rounder morphology of cells.
Furthermore, adhesive potential was analysed in SNB-19 cells
following mAb-blocking or siRNA-transfection. Both treatments
caused a significant decrease in adhesion to different ECMs except
vitronectin. Wild type SNB-19 cells adhered most effectively to
laminin, followed by fibronectin, collagen I, vitronectin and
tenascin C. A similar pattern was seen in both mAb- and siRNA-
treated cells. Laminin is arguably the most important of all ECM
proteins in the context of brain tumour invasion, while tenascin
C is expressed in high quantities in human gliomas [5,36]. The
tenascins are thought to facilitate glioma cell migration by
counteracting the adhesion activity of fibronectin to which they
bind [36,37]. The major ligand for CD44 is, however, hyaluronan
[38], therefore HA/hyaluronan would have been the best ECM to
Figure 4. Reduced motility rate in CD44/CD155-KD SNB-19 cells. Non-targeting siRNA treated SNB-19 cells were used as a control. a, Velocity of
cell movement (right panel) with cell tracking (left panel) analysed over a period of 72 h. The speed by which CD44/CD155-KD cells moved was
significantly reduced. b, Total distance moved by cells (right panel) with cell tracking (left panel) over a period of 72 h. The distance travelled by CD44/
CD155-KD cells was markedly decreased. Start position: white arrow; end position: black arrow. * indicates statistical significance compared to control.
doi:10.1371/journal.pone.0030691.g004
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Figure 5. Decreased adhesive potential of SNB-19 cells following mAb-blocking (a) and siRNA-KD (b) of CD44/CD155. Five different
human ECMs including collagen I, fibronectin, laminin, tenascin C and vitronectin were employed and BSA was used as the control substrate. For
each ECM substrate, the adhesive potential of manipulated SNB-19 cells (via either mAb-blocking or siRNA-KD) was compared with the relevant
control cells. Wild type SNB-19 cells served as a control in the mAb-blocking experiments whereas non-targeting siRNA treated SNB-19 cells were
used as a control in the siRNA-KD experiments. * indicates statistical significance compared to control.
doi:10.1371/journal.pone.0030691.g005
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assess the cell-ECM interaction. Unfortunately, it was not
commercially available and thus attempting to produce HA in-
house would have been costly and labour intensive. CD44 does,
however, interact with other ECM components including collagen,
fibronectin, laminin and fibrinogen [39]. CD155 binds specifically
to vitronectin and the CD155/vitronectin interaction can be
distinguished by a rapid complex formation [18]. Vitronectin binds
to several cell receptors particularly of the integrin type, therefore
plays a role in promoting cell attachment and invasion [4,40]. Our
results, however, show that CD155-depletion results in an en-
hanced cell adhesion to vitronectin, conflicting with the previously
published data [21]. This could be due to the compensatory activity
of CD44 and other adhesion mediators in the absence of CD155, as
suggested by our data that CD44 is a much stronger receptor for
vitronectin than CD155. These results can be further related to the
marked decrease in cell velocity and distance travelled by SNB-19
cells under similar treatment regimes. This can be explained as if
cells cannot adhere, they cannot move. Furthermore, no ECM
coating was used in the live cell imaging assay, suggesting that
glioma cells may produce their own autocrine stimulated ECMs [5].
CD155 co-localises with actin ruffles at the leading edges of
migrating cells, suggesting a potential association between CD155 and
actin cytoskeleton [20]. Previous studies have also revealed the co-
localisation of CD155 with integrin subunit especially av and b3,
known to mediate focal adhesion by forming physical transmembrane
link between ECM and the underlying cytoskeleton elements [4,41].
Therefore, CD155 expressed at the cell periphery and filopodia of
migrating cells may be associated with adhesion and directional
motility [20]. Integrins are involved in glioblastoma progression, with
av and b1 being central to glioma invasion [42,43]. In addition,
integrin heterodimers avb1 and avb3 are receptors for vitronectin and
are upregulated on glioma cells [44]. Moreover, CD44 mediates cell
movement arrest and adhesion by promoting integrin activation
[45,46]. To elucidate the mechanisms underlying CD44/CD155-
promoted glioma invasion, co-localisation of integrins or F-actin with
CD44/CD155 was investigated. We found strong evidence that
CD155 co-localises with avb1- and avb3-integrin at the leading edges
of glioma cells. A consequent decline in the expression level of
integrins and F-actin was seen following CD44/CD155-KD,
accompanied by reduced co-staining of CD155/integrins avb1 and
avb3. Our data suggest that CD155 plays a key role in glioma cell
invasion via its interaction with critical integrin subunits.
The driving force for cell movement is provided by dynamic
reorganisation of actin cytoskeleton, directing protrusion at the
front of the cell and retraction at the rear [47]. The key regulators
of actin cytoskeleton and adhesive structures are the Rho family of
small GTPases (Cdc42, Rac and Rho) which play specific roles in
cell motility and invasive phenotypes [37,48,49]. Previous studies
have shown that CD44 is redistributed to lamellipodia and
subsequently cleaved and shed from the cell surface when RhoA is
Figure 6. Expression of F-actin and integrins and their co-localisation with CD44/CD155 on GBM cells. a, Co-staining of F-actin (green/
left panels/L) or b1-integrin (green/right panels/R) with CD44 (red/top panels) and CD155 (red/bottom panels) on wild type UPAB cells. b, Co-
staining of avb1-integrin (green/L) or avb3-integrin (green/R) with CD44 (red/top panels) and CD155 (red/bottom panels) on wild type UPMC
(CD44 staining) and non-targeting siRNA treated SNB-19 cells (CD155 staining). All images in a and b have scale bars of 25 mm. c, Western blotting
showed reduced expression of F-actin and integrins (av, b1 and b3) in CD44/CD155-KD SNB-19 cells when compared to non-targeting siRNA treated
cells (control).
doi:10.1371/journal.pone.0030691.g006
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over-activated in human glioblastoma cells (U251MG) [50].
Additionally, CD44 engagement induces Rac1 activation, cyto-
skeleton rearrangement and CD44 cleavage at the newly
generated membrane ruffling areas during U251MG cell migra-
tion [51]. This raises the possibility that Rac1 activation upon
HA/CD44/Rac1 engagement may trigger intracellular signals
that induce CD44 cleavage and enhance tumour cell migration/
invasion. In the present study, a marked decrease was observed in
the expression level of Rac1/2/3 and RhoA in CD44/CD155-KD
SNB-19 cells accompanied by curbed invasiveness. CD44-KD also
caused obvious reduction in Cdc42 and RhoC expression. Based
on previous and present studies, it can be postulated that CD44
and CD155 may play important roles in cell migration/invasion
by engaging with Rho GTPases.
This study demonstrates the close proximity but not co-
localisation of CD44 and CD155 on the cell surface. For the first
time, CD44 and CD155 have been studied side-by-side to
understand their roles in cell migration/invasion and their
interaction with integrins and Rho GTPases. CD44/CD155-
silencing significantly inhibited the invasive phenotype of glioma
cells associated with decreased expression of some of the key
mediators of invasion, particularly F-actin, integrins, Rac 1/2/3,
RhoA and Cdc42. Our findings indicate that CD44 and CD155
are key players in glioma progression; CD44 playing a more
significant role in this context. In order to further investigate the
possibility of synergistic or co-operative role between CD44 and
CD155 in glioma invasion (not evidenced in this study) we plan to
carry out additional, in-depth studies of signal transduction
pathways. Indeed, an intimate knowledge of interactive processes
underlying invasion, e.g., those involving CD44 and/or CD155,
may prove valuable in the development of new therapeutic
strategies.
Materials and Methods
Ethics Statement
Biopsies from patients with glioblastoma were obtained under
Ethics permissions LREC 00-173 or KCH 11-094 or 11/SC/0048
in accordance with the National Research Ethics Service (NRES).
All patients consented to the use of biopsy material for research
purposes. Consent forms were read to and duly signed by
participating patients prior to biopsy.
Cells
Cell lines were cultured in Dulbecco’s Modified Eagle Medium
(Gibco) with 10% foetal calf serum (Sigma). The established
human glioblastoma cell line, SNB-19 (passage-44), was obtained
from the DSMZ German Brain Tumour Bank. Low-passage
human glioblastoma cell lines, UPAB (passage-8) and UPMC
(passage-7), were established in-house from biopsy-derived
Figure 7. Western blotting of Rho GTPases in CD44/CD155-KD SNB-19 cells. High levels of Cdc42, Rac 1/2/3, RhoA, RhoB and RhoC were
detected in non-targeting siRNA treated SNB-19 cells (control) whereas those proteins of interest were downregulated in CD44/CD155-KD cells.
doi:10.1371/journal.pone.0030691.g007
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cultures. Normal human astrocytes, CC-2565 (Lonza), were used
as controls.
Antibodies
Primary antibodies. Mouse monoclonal anti-CD44 (1:500
in immunocytochemistry; 1:25 in flow cytometry) and anti-CD155
(1:200; 1:20) were purchased from Chemicon and R&D systems
respectively. Blocking antibodies for CD44 (1:100) and CD155
(1:100) were obtained from Cambridge Biosciences. Mouse
monoclonal anti-F-actin (1:200) from Invitrogen and rabbit
polyclonal anti-integrin b1 (1:100), avb1 (1:100) and avb3 (1:200)
from Abcam were used for immunocytochemistry staining. Mouse
monoclonal anti-b-actin (1:500) (Sigma), anti-integrin av (1:250),
b1 (1:500) and b3 (1:2500) (BD Biosciences) and goat polyclonal
anti-GAPD (1:200) (Abcam) were used for Western blotting.
Secondary Antibodies. Horseradish peroxidase (HRP)-
conjugated IgG (Invitrogen) was used for chemiluminescent
detection in Western blotting (1:1000). Fluorochrome-conjugated
AlexaFluor-488 and -568 (Invitrogen) were used in flow cytometry
(1:500) and ICC (1:500).
siRNA-KD of CD44/CD155 in glioblastoma cells
SMARTpoolH siRNA (Dharmacon) targeting CD44 and
CD155 were transfected into SNB-19 cells following the
manufacturer’s instructions. Cells were incubated with siRNA
(100 mM) for 96 h to achieve .80% knockdown of CD44/CD155
and for 120 h in morphology assays. An AccellTM siRNA control
kit (Thermo Fisher Scientific) was used to test specificity and
stability of knockdown and efficiency of siRNA uptake by the cells,
including an AccellTM non-targeting pool siRNA as the negative
control and GADP-siRNA as the positive control. The non-
targeting pool siRNA consists of 4 siRNAs with at least 4
mismatches to any human gene, designed not to target any genes
in the human genome. It also distinguishes sequence-specific
silencing from non-specific side effects with minimal impact on cell
viability and cell phenotype. The GADP-siRNA serves to optimise
and monitor efficiency of siRNA delivery into SNB-19 cells. All the
siRNA transfection experiments were carried out at matching
concentrations and incubation period.
Immunocytochemistry (ICC)
ICC was performed according to the established protocols in
the laboratory [52]. Briefly, cells were seeded onto sterile
coverslips within a 6-well plate at 16105/well density and allowed
to reach 70–80% confluency before immunostaining. Cells were
fixed with 4% paraformaldehyde (PFA) (Sigma-Aldrich) and
permeabilised with 0.2% Triton X-100 (Sigma-Aldrich) for
intracellular antigen detection. Cells were then blocked with
10% serum/PBS (Sigma-Aldrich) and incubated with the relevant
primary antibody, followed by secondary antibody incubation.
Washes were carried out in PBS (5 min63) before and after each
antibody incubation and where double immunolabelling was
performed, antibodies (raised in different hosts) were cocktailed for
both incubation steps. Nuclei were counterstained with Hoechst
Blue (Sigma-Aldrich) then coverslips were mounted with Vecta-
shieldH (Vector Laboratories). The slides were viewed using a Zeiss
Axio ImagerZ1 fluorescence microscope. Images were captured
using Volocity Image Analysis Software (V5.2, Perkin Elmer).
Flow cytometry
Flow cytometry was carried out based on the standard protocols
[52]. For intracellular antigen staining, cells were permeabilised
with cytofix/cytoperm solution (BD Biosciences) at the beginning
of the procedure. Cells were blocked in 5% serum/PBS (Sigma-
Aldrich) prior to primary antibody incubation then washed with 5%
serum/PBS and incubated with secondary antibody. After the
incubation, cells were washed again and resuspended in 1% serum/
PBS then transferred to Fluorescence-activated cell sorting (FACS)
tubes (BD Biosciences). Shortly before analysis propidium iodide
(PI) (Sigma-Aldrich) was added to samples in order to enable cell
viability correction, except for intracellular antigen detection.
Analysis was performed on a four-colour-multi-parameter FACS
Calibur (BD Biosciences) equipped with a 488 nm argon gas laser
and a 635 nm red diode laser. Each sample was analysed in
triplicate plus one negative control (i.e. with primary antibody
omitted) and the experiment was repeated three times. The
expression level was assessed by the percentage of positive cell
population (positive cells (%)) and the mean amount of antigen
expressed by positive cells (fluorescence fold normalised against
negative control) as described previously [52].
Total internal reflected fluorescence (TIRF) microscopy
ICC specimens on microscope slides with coverslips (facing
downwards) were examined with a Zeiss Aviovert 200 M (inverted)
microscope incorporating a TIRF microscope (l=488 nm) on
coverslips. Fluorescence was detected using excitation wavelengths
of 488 nm (green), 568 nm (Red) and 405 nm (blue) with an argon
ion laser. A 1006 Plan-Apochromat oil immersion objective
(working distance= 0.10 mm) with a high numerical aperture
objective (NA.1.46) was used to obtain TIRF images. After the
internal reflectance angle was identified, images were acquired
using AxioVision software (V4.7, Carl Zeiss).
Confocal microscopy
ICC images were captured using the 406 oil immersion
objective of a Zeiss LSM 510 Meta Axioskop2 confocal
microscope. Fluorescence was detected using excitation wave-
lengths of 488 nm (green), 568 nm (red) and 405 nm (blue), with
an argon, HeNe1 and diode laser, respectively. Images were taken
using optimal settings for pinhole diameter, detector gain and
offset acquisition to detect positive immunofluorescence labelling
with minimal background. Multi-track image capture was used
with two channels so that separate channels could image different
colours to help prevent any overlap in excitation spectra. Identical
settings were then used to image negative controls in which
primary antibody was omitted.
Live cell imaging microscopy
Cells of interest were plated at 30% confluence in a 24-well plate
and left to adhere overnight prior the experiment. The Zeiss
Axiovert 200 M (inverted) live cell (time-lapse) microscope was then
set-up to image 1 point in each well, once every 30 min over 72 h to
monitor cell movement (37uC, 5% CO2, humid atmosphere). The
images were collated and movie sequences generated. Cell tracking
for the velocity and distance moved was enabled using the Volocity
software (V5.4, Perkin Elmer). Ten cells were tracked randomly for
each well and each experiment was done in triplicate and repeated
three times. Non-targeting siRNA treated SNB-19 cells were used as
the control.
Invasion assay
Cell invasion was assessed by the ‘Transwell’ modified Boyden
chamber technique [52]. Briefly, invasion was allowed to occur for
6 h in the incubator. A time-point analysis (2 h, 4 h, 6 h, 8 h,
10 h, 12 h) was carried out before choosing ‘6 h’ as the optimal
incubation time for the invasion assay which was further supported
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by our previous studies [26]. This provided enough time for SNB-
19 cells to invade prior proliferation based on the population
doubling time calculated for this cell line. Non-invading cells on
the upper surface of the filter were removed and invaded cells,
adherent on the lower filter surface, were characterised through
alkaline phosphatase vector red (Vectorlabs) staining. Images were
captured by a Zeiss Axiophot brightfield microscope using the
AxioVision software (V4.4, Carl Zeiss) and cells were counted in 5
random fields. For the mAb-blocking treatment, wild type SNB-19
cells were used as control and cells were incubated with 100 mg/
ml of the antibody during the invasion period. For the siRNA-KD
assay, non-targeting siRNA treated SNB-19 cells were used as
control. Each experiment was performed in triplicate. Invasion
was expressed as mean 6 SEM of the number of total cells
counted per well.
Proliferation assay
The Bromodeoxyuridine (BrdU) Cell Proliferation Assay Kit
was used to assess the proliferation rate of the cells according to the
manufacturer’s protocol (Chemicon). The 96-well plate was read
on a spectrophotometer microplate reader (POLARstar OPTIMA
BMG Labtech). The proliferation index was reflected by the
optical density (OD) reading. All tests were done in triplicate and
repeated three times. Controls used in mAb-blocking and siRNA-
KD assays were the same as those in the invasion assay (see above).
Adhesion assay
The ECM Cell Adhesion Array Kit (Chemicon) was used for
adhesion assay. The 96-well ECM Array plate consists of wells
coated with five different human ECMs (collagen I, fibronectin,
laminin, tenascin C, vitronectin) and wells coated with BSA which
serves as the control substrate. Cells were incubated for 2 h then
unbound cells were washed away. Adherent cells were lysed with
NaOH (1 M) and detected by the CyQuant GRH dye. Relative
cell attachment was determined using the same microplate reader
as above. All tests were carried out in triplicate and repeated three
times. Control cells used in mAb-blocking and siRNA-KD assays
were the same as those in the invasion assay (see above).
Western blotting (WB)
WB was performed according to a standard protocol. Briefly, cell
lysates were separated in 10% acrylamide SDS-PAGE gel and
proteins were detected using the primary antibodies and horseradish
peroxidase-conjugated secondary antibodies. Immunocomplexes
were revealed using an enhanced chemiluminescence reagent
(Cheshire Sciences) and light sensitive films (Amersham). The blot
was visualised and analysed with the GBOX Chemi XT16 system
(Synoptics). Wild type and non-targeting siRNA treated cells were
used as controls in various assays (refer to individual result and
figure legend). For siRNA-KD experiments, all transfected cells
were harvested after 96 h siRNA-incubation for lysate extraction.
Rho GTPases signal transduction pathway
The Rho-GTPase Antibody Sampler Kit (Cell Signaling
Technology) was used to investigate the effects of siRNA-CD44
and siRNA-CD155 on actin cytoskeleton reorganisation in SNB-
19 cells. Western blotting was performed to detect the proteins of
interest, as described above, using non-targeting siRNA treated
SNB-19 cells as a control. The antibodies used are as follows: anti-
Cdc42 (1:250), Rac1/2/3 (1:500), RhoA (1:500), RhoB (1:500)
and RhoC (1:500). All antibodies were rabbit polyclonal.
Statistical analysis
Statistical analyses were performed using one-way ANOVA
followed by Tukey’s multiple comparison post test with p,0.05
being regarded as significant. The software package GraphPad
Prism 3.02 was used and all data are presented as mean values.
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